AZ8838 is a potent, competitive, allosteric, orally active non-peptide small molecule antagonist of PAR2 with a pK i of 6.4 for hPAR2.
性状
Solid
IC50 & Target[1][2]
PAR2 6.4 (pKi)
体外研究(In Vitro)
AZ8838 binds in an occluded pocket.AZ8838 is a potent antagonist against SLIGRL-NH2 in the Ca assay with a pIC50 of 5.70?±?0.02.AZ8838 shows a potency trend when inhibiting IP1 production (pIC50 = 5.84?±?0.02).AZ8838 attenuates both peptide-induced phosphorylation of ERK1/2 (pIC50 = 5.7?±?0.1) and β-arrestin-2 recruitment (pIC50 = 6.1?±?0.1). has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
AZ8838 (10?mg/kg; p.o.; 2?h prior) is anti-inflammatory in a PAR2 agonist-induced rat paw oedema model. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: Wistar rats, PAR2 agonist 2f-LI
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Kennedy AJ, et al. Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition. Commun Biol. 2020 Dec 17;3(1):782.
溶解度数据
In Vitro: DMSO : 200 mg/mL (853.72 mM; Need ultrasonic)配制储备液